Eli Lilly

Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
AbbVie and Lilly have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
ABPI
Tue, 01/17/23 - 10:38 am
AbbVie
Eli Lilly
UK
NHS
drug pricing
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
Thu, 01/12/23 - 10:27 am
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab
Lilly, Biogen and more gear up for blockbuster launches in 2023: report
Fierce Pharma
Wed, 01/11/23 - 11:00 pm
Clarivate
drug launches
Eli Lilly
Biogen
GSK
Bristol Myers Squibb
Eli Lilly Had a Strong Year in 2022. It's Expecting an Even Better 2023.
Motley Fool
Wed, 01/11/23 - 10:48 am
Eli Lilly
earnings
JPM23: Lilly has a full plate, as CMO jokes, 'we need to leave J.P. Morgan and get back to work'
Fierce Biotech
Mon, 01/9/23 - 10:48 pm
Eli Lilly
JPMHC 2023
CMOs
TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
Businesswire
Mon, 01/9/23 - 10:37 am
Eli Lilly
TRexBio
tregs
drug development
5 FDA decisions to watch in the first quarter
BioPharma Dive
Mon, 01/9/23 - 10:27 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Lilly's Prevail, Capsida partner to develop gene therapies for nervous system diseases
BioPharma Dive
Wed, 01/4/23 - 05:32 pm
Eli Lilly
gene therapy
Capsida
CNS disorders
Prevail Therapeutics
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts
Fierce Pharma
Tue, 01/3/23 - 10:10 am
Eli Lilly
Merck
PeptiDreams
peptides
drug delivery
Could This Drug News Give a Lift to Eli Lilly Stock?
Motley Fool
Mon, 01/2/23 - 06:27 pm
Eli Lilly
Rezvoglar
diabetes
Sanofi
Lantus
biosimilars
long-acting insulin
Lilly doubles down on ProQR's RNA tech in $75M deal expansion, spurring biotech's much-needed share rally
Fierce Biotech
Thu, 12/22/22 - 10:58 am
Eli Lilly
ProQR Therapeutics
genetic medicine
RNA
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
Motley Fool
Thu, 12/22/22 - 10:46 am
Eli Lilly
Alzheimer's disease
Catalysts ahead for the smaller players
EP Vantage
Wed, 12/21/22 - 11:19 am
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Eli Lilly diabetes drugs Mounjaro and Trulicity in short supply, FDA says
Medical Marketing and Media
Mon, 12/19/22 - 10:17 pm
Eli Lilly
diabetes
drug shortages
Mounjaro
Trulicity
Big pharma’s new year catalysts
EP Vantage
Mon, 12/19/22 - 11:05 am
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Mon, 12/19/22 - 11:02 am
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Lilly Plunks Down up to $731M in GPCR Pact with Sosei
BioSpace
Fri, 12/16/22 - 10:27 am
Eli Lilly
Sosei
drug discovery
drug development
diabetes
metabolic disorders

Pages